Tribenoside

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Tribenoside is an anti-inflammatory agent that reduces vascular permeability and causes vasoconstriction to treat internal and external hemorrhoids.

Generic Name
Tribenoside
DrugBank Accession Number
DB13227
Background

Anti-inflammatory agent used in edema of extremities, varicose veins & phlebitis.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 478.585
Monoisotopic: 478.235538815
Chemical Formula
C29H34O6
Synonyms
  • TBGF
  • Tribenoside
  • Tribenosido
  • Tribenosidum
External IDs
  • 21401-BA
  • Ba 21401
  • BG-356

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatHemorrhoidsCombination Product in combination with: Lidocaine (DB00281)•••••••••••••••••• •••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PROCTO - GLYVENOL® SUPOSITORIOSTribenoside (400 mg) + Lidocaine (40 mg)SuppositoryRectalDELPHARM HUNINGUE S.A.S2006-11-10Not applicableColombia flag
PROCTO GLYVENOL %5 +%2 KREM, 30 GTribenoside (5 %) + Lidocaine (2 %)CreamRectalRECORDATİ İLAÇ SAN. VE TİC. A.Ş.2011-05-18Not applicableTurkey flag
PROCTO-GLYVENOL %20 +%2 SUPOZITUAR, 10 ADETTribenoside (20 %) + Lidocaine (2 %)SuppositoryRectalRECORDATİ İLAÇ SAN. VE TİC. A.Ş.2011-05-18Not applicableTurkey flag
PROCTO-GLYVENOL CREMATribenoside (5 g) + Lidocaine hydrochloride (2.12 g)CreamRectal; TopicalGSK CONSUMER HEALTHCARE S.A.2006-11-102023-09-14Colombia flag

Categories

ATC Codes
C05AX05 — TribenosideC05CX01 — Tribenoside
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
O-glycosyl compounds
Alternative Parents
Benzylethers / Monosaccharides / Tetrahydrofurans / Secondary alcohols / Oxacyclic compounds / Dialkyl ethers / Acetals / Hydrocarbon derivatives
Substituents
Acetal / Alcohol / Aromatic heteromonocyclic compound / Benzenoid / Benzylether / Dialkyl ether / Ether / Hydrocarbon derivative / Monocyclic benzene moiety / Monosaccharide
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Z7N0Y673NU
CAS number
10310-32-4
InChI Key
ULLNJSBQMBKOJH-VIVFLBMVSA-N
InChI
InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3/t25-,26-,27-,28-,29?/m1/s1
IUPAC Name
(3R,4R,5R)-4-(benzyloxy)-5-[(1R)-1,2-bis(benzyloxy)ethyl]-2-ethoxyoxolan-3-ol
SMILES
CCOC1O[C@H]([C@@H](COCC2=CC=CC=C2)OCC2=CC=CC=C2)[C@H](OCC2=CC=CC=C2)[C@H]1O

References

General References
  1. TITCK Product Information: Procto-Glyvenol (tribenoside/lidocaine hydrochloride) rectal cream [Link]
  2. TITCK Product Information: Procto-Glyvenol (tribenoside/lidocaine hydrochloride) rectal suppositories [Link]
ChemSpider
169970
RxNav
38557
ChEBI
91780
ChEMBL
CHEMBL3301681
Wikipedia
Tribenoside

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedScreeningColonic Adenomatous Polyps / Colorectal Cancer / Colorectal Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral400.000 mg
Capsule, liquid filledOral400 mg
SuppositoryRectal
CreamRectal
CreamRectal; Topical
CapsuleOral400 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00325 mg/mLALOGPS
logP4.13ALOGPS
logP5.17Chemaxon
logS-5.2ALOGPS
pKa (Strongest Acidic)12.36Chemaxon
pKa (Strongest Basic)-3.6Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area66.38 Å2Chemaxon
Rotatable Bond Count13Chemaxon
Refractivity133.51 m3·mol-1Chemaxon
Polarizability52.51 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00b9-1117900000-fd47ef2f7dfeba13f36c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00or-0398100000-63de29d311ac558d32f1
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00bc-3309600000-d207c4fd62ce14b4433b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00or-3069000000-c1ace2d19f91e46e2e21
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01sl-3978300000-b9e05b4d8be1a3ea3990
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0007-9131100000-931c4f176aba0c5de660
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-200.99489
predicted
DeepCCS 1.0 (2019)
[M+H]+203.39046
predicted
DeepCCS 1.0 (2019)
[M+Na]+209.303
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:38 / Updated at June 05, 2021 09:13